Harmony Biosciences Holdings, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging +12.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.97 | $1.28 | +32.0% | Beat | |
| Q1 FY26 | $0.76 | $0.55 | -27.6% | Miss | |
| Q4 FY25 | $0.84 | $0.38 | -54.8% | Miss | Q4 FY25 call |
| Q3 FY25 | $0.92 | $0.87 | -5.4% | Miss | |
| Q2 FY25 | $0.78 | $0.68 | -12.8% | Miss | |
| Q1 FY25 | $0.59 | $0.78 | +32.2% | Beat | |
| Q4 FY24 | $0.74 | $0.85 | +14.9% | Beat | |
| Q3 FY24 | $0.64 | $0.79 | +23.4% | Beat | |
| Q2 FY24 | not reported | $0.20 | not reported | not reported | |
| Q1 FY24 | $0.64 | $0.67 | +4.7% | Beat | |
| Q4 FY23 | $0.74 | $0.45 | -39.2% | Miss | |
| Q3 FY23 | $0.67 | $0.63 | -6.0% | Miss |
Back to HRMY overview · HRMY holders · HRMY KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.